GoBroad is dedicated to advancing hematologic stem cell transplantation (HSCT) as a cornerstone of treatment for complex blood disorders, including leukemia, myeloma, thalassemia, and rare immune deficiencies. With over 1,500 beds across seven specialized hospitals in China, our team integrates cutting-edge technology, multidisciplinary expertise, and patient-centered care to redefine outcomes for individuals requiring HSCT. Our innovative protocols, such as TCRαβ+T cell-depleted transplants and Double-Insurance Dual HSCT, reflect our focus on improving survival rates and quality of life for patients worldwide.

Innovative HSCT Techniques for Complex Blood Disorders

Our approach to hematologic stem cell transplantation addresses both malignant and non-malignant conditions with precision. For thalassemia major, GoBroad Double-Insurance Dual HSCT achieves a 97.6% four-year disease-free survival rate, offering hope where options were once limited. The TCRαβ+T Cell Depleted HCT (TDH) minimizes graft-versus-host disease (GVHD) risks, enhancing safety for recipients of all ages. In cases of refractory leukemia, we combine sequential CAR-T therapies with HSCT to achieve remission in patients who have relapsed after traditional treatments. With expertise spanning infants to elderly adults, our hospitals have completed thousands of transplants, supported by 100+ clean rooms for cell processing and rigorous safety standards.

Expanding HSCT Access for Rare Hematologic Diseases

We pioneer HSCT for rare conditions, setting global benchmarks in care. Our team performed the world’s first allogeneic HSCT for lysinuric protein intolerance (LPI) and has successfully treated severe combined immunodeficiency (SCID), chronic granulomatous disease (CGD), and Wiskott-Aldrich syndrome (WAS). These milestones stem from integrating genetic diagnostics, molecular profiling, and collaboration across specialties. For example, patients with hemophagocytic lymphohistiocytosis (HLH) benefit from rapid interventions coordinated by hematologists, immunologists, and transplant experts. Our work ensures underserved rare disease populations receive timely, effective solutions.

Multidisciplinary Care: The Foundation of Our Success

Our HSCT achievements rely on collaboration among hematologists, radiologists, immunotherapy specialists, and supportive care teams. Dr. Chunrong Tong, leading our hematology department, exemplifies this model. With over 30 years of experience, her team merges chemotherapy, targeted therapies, and CAR-T with HSCT to personalize treatments for refractory blood cancers. Our clinical research division accelerates progress through trials on novel drug combinations and CAR-T targets like CD19 and CD22. This synergy between research and practice allows us to offer advancements such as post-HSCT consolidation therapies for secondary plasma cell leukemia.

Conclusion

GoBroad continues to redefine hematologic stem cell transplantation, delivering transformative outcomes for patients with leukemia, rare diseases, and complex blood disorders. By advancing techniques like TCRαβ+T cell depletion and fostering multidisciplinary collaboration, we stand as a global leader in HSCT. Families navigating hematologic stem cell transplantation challenges trust our expertise to provide safe, innovative, and compassionate care. To learn more about our hematologic stem cell transplantation programs, connect with our international patient services team or explore our official platforms for detailed insights.